In today's episode, Sophie discusses psoriatic arthritis with Dr Ryan Hum from The University of Manchester.

Psoriatic arthritis affects between 0.1% and 1% of the general population globally, and appears to be more prevalent in certain regions. It affects men and women equally and typically appears between the ages of 30 and 55 years. Psoriatic arthritis tends to be more common in people with psoriasis affecting around 20% of individuals, but estimates can depend on the inclusion criteria studies use.

We touch on the pathogenesis of psoriatic arthritis and how it might manifest in a patient, as well as the contribution of synovial inflammation and how research into this topic contributes to our understanding of the disease. We also discuss the reasons psoriatic arthritis research is in the early stages when compared to rheumatoid arthritis. 

The Review discussed can be found here: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00231-0/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this episode, we’re tackling a condition that affects over 374 million people worldwide—knee osteoarthritis (OA). As the most common site of OA, knee OA is a leading cause of disability and accounts for more than 12 million disability-adjusted life years globally. With prevalence rising steadily due to aging populations and increasing obesity rates, the burden of knee OA is projected to climb even further in the coming decades.

We speak with the lead author of a new study published in The Lancet Rheumatology, Dr Scott Uhlrich, from the University of Utah. The study offers fresh insights into the management of knee OA through personalised gait retraining. We’ll explore the study’s design, its clinical implications, and what the future might hold for patients with knee OA.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00151-1?dgcid=buzzsprout_icw_podcast_September_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this episode, we'll be discussing an issue that affects millions of people globally - low back pain. We will find out why the burden of low back pain is so high, why current management is so ineffective, what we can do from a research and care perspective to improve outcomes for patients, and whether prevention is the way forward. 

We’ll also discuss a couple of papers that have been recently published in The Lancet Rheumatology looking at longer-term treatment options for low back pain, and how useful they are.

Read the Systematic Review:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00064-5/abstract?dgcid=buzzsprout_icw_podcast_August_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this episode Professor Vibeke Strand discusses polymyalgia rheumatica (or PMR), a common inflammatory rheumatic disease that significantly impairs patients’ quality of life, causing fatigue, pain, and physical disability, especially in relapsing cases that often require long-term glucocorticoid treatment. However, these treatments come with considerable side effects, and many patients do not respond to treatment.

We also cover her recent publication, which explores the patient reported outcomes of a trial using sarilumab, a monoclonal antibody targeting the inflammatory cytokine IL-6, which has now been approved for treatment of PMR in the USA.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00041-4/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

This is a joint podcast between The Lancet Rheumatology and The Lancet Regional Health - Western Pacific with Prof Xue Li. Biologics have become a mainstay of treatment in Rheumatology in Western populations, but in many parts of Asia, especially lower-and-middle-income countries, there remains substantial inequity in access due to differences in availability and affordability.

In this episode, we explore the factors that may have delayed the popularisation of biologics in Asia, any recent policy changes and the role of biosimilars in this landscape.

Read the full article:

https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(22)00121-3/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanwpc

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research.

VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threatening, inflammatory condition primarily affecting men. It's caused by a mutation in the UBA1 gene, leading to systemic inflammation and progressive bone marrow failure. The condition can manifest with a variety of symptoms, including fevers, fatigue, rashes, and joint pain, and can affect various organs and tissues.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

This is the third and final episode of our mini-series on cell-based therapies in rheumatology, with Professor Fabian Müller and Dr Melanie Hagen from the Erlangen University, Germany. We discuss their recently published a study on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy in patients with autoimmune disease, as well as the recent successes of CAR T-cell therapy, ideal patient selection, and future directions.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00091-8/fulltext?dgcid=buzzsprout_icw_podcast_Jun_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

This is the second episode of a mini series on cell-based therapies in rheumatology, with Prof. Dominique Farge discussing the use of allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) as treatment for systemic lupus erythematosus (SLE). 

We cover the limited options currently available for people with severe or refractory SLE, the complexities in using MSCs, Prof. Farge's recent study results, and how these results fit in with the evidence available, as well as the future for this area of research. 

You can find the study here:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00298-4/fulltext?dgcid=buzzsprout_icw_podcast_25-04-25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

The first episode of a mini series on cell-based therapies in rheumatology, with Prof Rebecca Marsh and Grant Schulert discussing the use of allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00275-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv